Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199156 | 1.00 | DRD4 (0.37) | DRD4DRD2PSEN1PSEN2APH1B | |
| SCHEMBL19129893 | 1.00 | DRD4 (0.37) | DRD4DRD2PSEN1PSEN2APH1B | |
| SCHEMBL8206953 | 0.75 | DRD4 (0.45) | DRD4DRD2PDE10A | |
| SCHEMBL22908472 | 0.75 | PSEN1 (0.37) | DRD4DRD2PSEN1PSEN2APH1B | |
| SCHEMBL22151085 | 0.74 | PLAU (0.37) | DRD4DRD2PSEN1PSEN2APH1B | |
| SCHEMBL22429827 | 0.74 | GRM5 (0.38) | — | |
| SCHEMBL23799094 | 0.74 | GRM5 (0.38) | — | |
| SCHEMBL20987585 | 0.74 | GRM5 (0.38) | — | |
| SCHEMBL23799156 | 0.74 | GRM5 (0.38) | — | |
| SCHEMBL22908512 | 0.74 | PSEN1 (0.37) | DRD4DRD2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | DRD4 2450/4885DRD2 1865/4885PSEN1 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.